- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Prenatal diagnosis using genetic sequencing and identification of a novel mutation in MMACHC
© Zong et al. 2015
Received: 30 September 2014
Accepted: 2 July 2015
Published: 7 July 2015
Combined methylmalonic aciduria and homocystinuria, cobalamin(cbl)C deficiency, is a rare disorder of intracellular vitamin B12(cbl) metabolism caused by mutations in the MMACHC gene. Both genetic and biochemical approach have been established to diagnose children and fetuses with cblC deficiency, while in China there is no report of prenatal genetic diagnosis of cblC deficiency. The aim of the present study was to characterize the mutational spectrum of cblC deficiency and investigate the feasibility of genetic-sequencing-based prenatal diagnosis for cblC deficiency.
10 pedigrees were recruited in this study with the probands clinically and biochemically confirmed combined methymalonic aciduria and homocystinuria. Peripheral blood samples were collected for MMACHC genetic test from the probands and their parents (4 probands had already dead) and 50 control subjects. The entire coding region and adjacent splice sites of MMACHC were sequenced. After the genotypes of the pedigrees were identified, chorionic villi sampling were performed for 3 high-risk pregnant women for prenatal genetic diagnosis.
A total of 7 mutations were identified: c.217C > T (R73X), c.394C > T (R132X), c.463G > C (G155R), c.609G > A (W203X), c.616C > T (R206W), c.658-660delAAG (220delK), and c.567dupT (I190YfsX13), as well as 2 polymophsims: c.321G > A(V107V), c.-302G > T. And G155R is a novel mutation that haven’t been reported in the literatures. All the 6 probands identified with compound heterozygous mutations or homozygous mutations of MMACHC gene, and all the parents of the probands were found to have one MMACHC mutation at a heterozygous level. Prenatal diagnosis of fetuses from 3 families with a child affected cblC deficiency showed that one fetus had the same compound heterozygous mutations as the proband, one did not have MMACHC mutation, and the third fetus had a mutation at a heterozygous level of MMACHC gene. Results from the follow-ups were consistent with the prenatal diagnosis.
A novel mutation p.G155R of the MMACHC gene is identified. Genetic diagonsis is an accurate and convenient method for prenatal diagnosis and early intervention of combined methylmalonic aciduria and homocystinuria.
Methylmalonic acidemia (MMA), the most common inborn disorder of organic acid metabolism, is inherited as an autosomal recessive disease caused by defects of methylmalonyl CoA mutase (MCM) or disorders of intracellular cobalamin metabolism . MMA can be classified as isolated methymalonic acidemia and combined methylmalonic acidemia and hyperhomocysteinemia based on biochemical features. Combined methymalonic aciduria and homocystinuria consists of four subtypes, MMACHC(cblC), MMADHC (cblD combined, cblD-MMA and cblD-HCY), LMBRD1(cblF) and ABCD4(cblJ) . All of them may cause the deficiency of methylcobalamin (MeCbl) and adenosylcobalamin (AdoCbl) and then reduce the activity of methionine synthase and methylmalonyl CoA mutase (MCM). Thus both methylmalonic acid and homocysteine will be accumulated in the blood and urine [3, 4]. In China, 80 % of patients with MMA are combined methylmalonic acidemia and hyperhomocysteinemia , among which the cblC type is the most common. The gene associated with the cblC defect is MMACHC (OMIM 277400), which maps to chromosome region 1p34.1 and consists of 5 exons and expressing a 5.2 kb mRNA encoding a 282 amino acid protein . To date, 77 mutations have been identified in this gene, and genotype-phenotype correlations have been studied [7–10]. Based on the age at onset, two forms of cblC deficiency have been described [3, 4]. Early-onset patients present in the first year of life with feeding difficulties, hypotonia, developmental delay, seizures, pigmentary retinopathy and anemia. Late-onset patients exhibit ataxia, dementia, psychosis and other neurologic symptoms after 4 years old [1, 3].
With the application of tandem mass spectrometry and gas chromatography–mass spectrometry (GC-MS), more and more affected children have benefitted from early diagnosis and treatment, greatly reducing mortality and morbidity in children with MMA. Although MMA is a partially treatable disorder, both the high mortality during the acute phase and the chronic damage to the nervous system, will lower the quality of patient’s life and increase the family economic burden. The most effective intervention is to avoid the birth of children with MMA through prenatal diagnosis. Many successful techniques for prenatal diagnosis of combined methymalonic aciduria and homocystinuria have been reported in China and other countries, including measuring the activity of methylmalonyl-CoA mutase in the amniotic fluid, amniotic fluid cells and chorionic cells and quantification of cbl metabolites in amniotic fluid cells [11, 12]. In recent years, analysis of acylcarnitine analysis by electrospray tandem mass spectrometry(ESI/MS/MS) has been used in prenatal diagnosis. A combination of genetic and biochemical analyses have been reported, while in China there is no report of prenatal diagnosis through simple genetic diagnosis. In the present study, MMACHC mutations were analyzed in 10 pedigrees of combined methymalonic aciduria and homocystinuria (cblC type) and a novel mutation was identified. Prenatal genetic diagnosis was performed for 3 families.
Ten pedigrees were recruited for the study which came to our hospital, the Third Affiliated Hospital of Zhengzhou University, and the Children's Hospital of Zhengzhou from March 2011 to April 2013. There was no consanguinity among the children, and none of their parents was consanguineous marriage. Children from 6 families were directly diagnosed with combined methymalonic aciduria and homocystinuria based on clinical features. For the other four families, the probands were diagnosed postmortem (with complete clinical information), because the four probands presented severe symptoms within 3 months and died within 1 years old.
All patients showed different levels of respiratory infections, feeding difficulties, malnutrition, seizures, drowsiness, seizures, hypotonia, and psychomotor retardation. Urinary organic acid analysed by gas chromatography/mass spectrometry (GC-MS,QP2010, Schimadzu, Japan) showed high levels of methylmalonic acid. Serum total homocysteine was elevated determined by fluorescence polarization immunoassay (IMX automatic analyzer,Abbott, the USA) .
This study was approved by the Medical Ethics Committee in the First Affiliated Hospital of Zhengzhou University. All of the analyzed samples were obtained with the parents’ informed consent.
2 ml peripheral venous blood was taken from the 6 probands and 10 couples of parents, and then anticoagulated by ethylenediaminetetraacetic acid disodium salt (EDTAK2). The transabdominal chorionic villi sampling were performed with ultrasonic guidance for the high-risk women at 10 to 13 + 6 weeks of gestation. Genomic DNA was extracted from peripheral blood samples and chorionic villi samples using the DNA extraction kit (TIANGEN Biotech, Beijing, China) according to the manufacturer’s instructions.
PCR reactions and DNA sequencing
PCR primers for mutation analysis of MMACHC
Bioinformatics analysis of sequence variations
By searching the HGMD database, Exome Variant Server and ExAC browser, the new mutations were identified and the frequency of each known variantion is available. The analysis software ClustalW was used to compare the homologous sequences of human MMACHC with other species. PROVEAN prediction and Polymorphism Phenotyping (PolyPhen) were performed to analyze the impact of new mutations. The corresponding fragments of MMACHC from 50 unrelated healthy individuals were amplified and sequenced.
After the genotype of the probands and their parents were identified, prenatal genetic diagnosis was performed for the 3 fetuses at 10 to 13 + 6 weeks’ gestation. DNA was extracted from chorionic villi samples and mutations of the MMACHC gene were detected. To exclude contamination from the mother, the PowerPlex 16 HS System kit (Promega, Madison, WI, USA) were used and the results were analyzed using ABI3130xl (Life Technologies, USA) and the software GeneMapper v3.2. The evaluation criteria for absence of contamination were defined as follows: the fluorescence peaks of the gene-sites of the fetus were also appeared in its parents, and there is only one fluorescence peak acquired from its mother. The prenatal genetic diagnosis will be carried out within 1 week.
Specimens of umbilical cord blood or fibroblast cells from the three fetuses were collected for genetic diagnosis. Organic acid levels of urine and serum total homocysteine were detected for two newborns at 1 month old.
Analysis of MMACHC mutations
Mutational analysis, clinical data and prenatal diagnosis of combined MMA and HC families
(age and clinical details)
Dead of severe malnutrition at 6 months old
1.5y,developmental delay HC decreased to 60 μM
MMA decreased to 24.6 μM
Dead at 1 month old
Dead at 8 month old
HC, MMAare normal
developmental delay, malnutrition
15 months, taking medicine promptly and properly for a period of time, the patient has being in good recovery
Dead at 4 months old
Visual inattention nystagmus
6 months, Can’t raise his head, developmental delay
The variation c.-302 T > G located in the 5’ untranslated region, and c.321G > A (V107V) was a synonymous mutation, both of them are known polymorphisms.
Prenatal diagnosis of MMACHC gene and follow-up
In family 1, the mother of one deceased proband was found to have 220delK heterozygous mutation and the father had W203 heterozygous mutation. The fetus was identified with compound heterozygous mutation of 220delK/W203X, and was affected cblC deficiency. In family 6, the proband had compound heterozygous mutations of R206W/W203X,while the mother had R206W mutation and the father had W203X mutation respectively. The fetus was identified as a heterozygous carrier of R206W mutation. In family 8, the proband had W203X mutations at a homozygous level, and both the parents had one W203X allele, while the fetus did not have any MMACHC mutations (Table 2). Chorionic villi tissues collected from the fetuses of were analyzed to exclude maternal contamination using the PowerPlex 16 HS System kit, thus the results of gene detection in this study was reliable.
After genetic counseling, family 1 chose to terminate the pregnancy. The fetal fibroblast cells were collected for genetic test, and the result were consistent with that of the prenatal diagnosis. Family 6 and 8 chose to continue the pregnancies, and the umbilical cord blood was taken for gene diagnosis after the childbirth. The results were consistent with that of prenatal diagnosis. Organic acid levels of urine and serum total homocysteine of the two newborns were normal at 1 month old.
In this study, 9 variations in MMACHC were identified in 10 pedigrees with cblC deficiency including a novel mutation, G155R. By transabdominal chorionic villi sampling and DNA sequencing, genetic prenatal diagnose is performed and proved to be accurate and convenient. Among 3 cases of prenatal diagnosis, one fetus was found to be affected by cblC deficiency with compound heterozygous mutations of MMACHC, one fetus was determined to be a mutation carrier, while the third fetus had a normal genotype. Genetic sequencing after birth for the second and the third babies confirmed the results of prenatal diagnosis.
To date, 77 diferent mutations in the MMACHC gene have been reported. Among these mutations, several mutations are common but ethnic-specific. The c.271dupA mutation is the most common allele in Europeans, with a mutation frequency of 40 %, and ususlly occurred in early-onset cases. The c.394C > T mutation at a homozygous level occurred mostly in Native American and Middle Eastern patients, and is associated mostly with a late-onset disease [8, 9]. The mutation c.609G > A (W203X) occurred most frequently in patients in East Asia [15–17].
Han  reported that 156 mutations were found in 158 disease alleles in 79 Chinese patients with combined methymalonic aciduria and homocystinuria. The mutations c.609G > A (W203X), c.658_660delAAG (K220del), c.482G > A (R161Q), c.394C > T (R132X), and c.80A > G (Q27A) were the most frequent and accounted for 80 % of all mutations. Among these 5 mutations, the c.609G > A mutation was the most common, accounting for 50 %, followed by the c.658_660delAAG mutation, which accounted for 9 %. In this study, 10 c.609G > A mutations were found in 20 alleles accounting for 50 % of the total mutations, which further confirmed that the c.609G > A mutation in MMACHC was the hot spot in Chinese patients. Another recent study proposed that the c.609G > A mutation may be specific to East Asian populations .
A total of seven mutations and two polymorphisms were detected in this study. The mutations c.217C > T, c.394C > T and c.609G > A lead to the encoding of a stop codon at amino acid residue 73,132 and 203 resulting in premature termination of translation. The c.658_660delAAG mutation, located in the C-terminal region of MMACHC, causes deletion of lysine at residue 220. The c.616C > T (R206W) mutation is first reported in China, and its function have not been reported so far. The c.567dupT mutation causes a frameshift at codon 189 and a premature termination at codon 202. The c.463G > C (G155R) mutation is reported for the first time although c.464G > A (p.G155E) mutation at the same codon has been reported previously . The MMACHC glycine 155 is highly conserved among many species and PROVEAN and PolyPhen analysis for p.G155E suggested pathogenic. Among seven mutations found in this study, six were located in exon 4. Liu et al.  showed that exon 3 and exon 4 are mutation hot spots. Therefore genetic screening of cbl deficiency may be performed preferentially in exon 3 and exon 4 of MMACHC.
In general, late-onset patients have better survival and response to treatment compared with early-onset patients. As an early-onset patient, patient 6 in this study had been given treatment with hydroxycobalamin, carnitine, betanine and folinic acid, as well as rehabilitation programs promptly after diagnosis. During follow-up at 3 years old, we found that his urine levels of MMA decreased to normal and plasma levels of homocystenuria decreased to 10.6 μmol/l. The result confirmed the importance of early intervention of the disease.
In this study, 3 families with probands affected the early-onset cbl deficiency underwent prenatal genetic diagnosis. W203X mutation was found at a homozygous level in one family, and at a heterozygous level for the other two families. Wang reported that in 31 cases of early-onset cbl C deficiency, 25 (80.6 %) had the W203X mutation, indicating that the W203X mutation may be associated with early-onset phenotype . However, more data are needed to confirm this correlation.
The early-onset cbl deficiency is a severe neonatal genetic disease. Although the outcome will be better through early detection and treatment, most children die before one year old. Prenatal diagnosis is helpful and necessary to parents who want a second child. In families with deceased probands, genetic diagnosis can be made by testing the parental MMACHC genes. If both of the parents have a MMACHC mutation at a heterozygous level, the proband’s genotype can be deduced. Prenatal diagnosis for cbl deficiency is sought for terminating an affect pregnancy, instituting treatment during pregnancy or alleviating mental pressure of the couples and so on. Prenatal OHCbl administration may reduce the maternal metabolites, however the complications of cbl deficiency such as retinopathy could not be ameliorated . In this study, chorionic villi samples were collected in the first-trimester pregnancy for prenatal genetic diagnosis for 3 families. The fetus of the first family was identified with 220delK/W203X compound heterozygous mutation and the parents chosed terminate the pregnancy. After abortion the fibroblast cells of that fetus were tested for MMACHC mutations, and the results were consistent with the prenatal diagnosis. The fetus of the second family had R206W mutation at a heterozygous level, while the third fetus was normal. After genetic counseling, the two families decided to continue their pregnancies. After the babies were born, they were determined to be healthy by physical examination and laboratory tests. There are several approaches to make biochemical prenatal diagnosis of MMA . Reaserchers could determine the methylmalonate in amniotic fluid(AF) and maternal urine, measure the mutase reaction and cobalamin metabolism in cultured amniocytes, study the [14C]-propionate incorpation, analysis acylcarnitine, and assay the MCM activity in chorionic villi(CV) . There seems to be a lack of consensus on the most reliable method, and preferred sample on which to conduct these investigations. And it is reported that the results could be false nagtive/positive [2, 17]. Although the metabolic analysis of amniotic fluid will be carried out simply, the molecular genetic testing is the best method to make prenatal diagnose in the first trimister,since amniocentesis shouldn’t be performed before the 16th gestational week to avoid complications. Our success with prenatal genetic diagnosis of cblC deficiency shows that it is acurate and economical. It could also be an effective method of genetic screening for affected families. But the information of the proband or its parents must be avaliable, and maternal contamination of the DNA sample should be excluded by marker analysis. Preimplantation genetic diagnosis could also be considered for the families whose pathogenic mutation have been identified.
We present the molecular confirmation of infantile onset cobalamin C type-combined methylmalonic acidemia and homosystinuria in 6 probands and their parents, as well as 4 additional couples with diseased children affected cblC deficiency, and a novel mutation of the MMACHC gene, p.G155R is identified. We also performed prenatal diagnosis using CVS(chorionic villi sampling) and DNA sequencing for three high-risk pregnant women successfully.
Research supported by Grant from the Henan Province Medical Science and Technique Foundation (#201303015).
- Fowler B, Leonard JV, Baumgartner MR. Causes of and diagnostic approach to methylmalonic acidurias. J Inherit Metab Dis. 2008;31:350–60.View ArticlePubMedGoogle Scholar
- Nuria CC, David A, Charles PV: Disorders of intracellular cobalamin metabolism. Gene Reviews[Internet].Google Scholar
- Carrillo-Carrasco N, Chandler RJ, Venditti CP. Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management. J Inherit Metab Dis. 2012;35:91–102.View ArticlePubMedGoogle Scholar
- Carrillo-Carrasco N, Venditti CP. Combined methylmalonic acidemia and homocystinuria, cblC type. II. Complications, pathophysiology, and outcomes. J Inherit Metab Dis. 2012;35:103–14.View ArticlePubMedGoogle Scholar
- Liu YP, Ma YY, Wu TF, Wang Q, Li XY, Ding Y, et al. Abnormal findings during newborn period of 160 patients with early-onset methylmalonic aciduria. Zhonghua er ke za zhi Chi J pediatr. 2012;50:410–4.Google Scholar
- Lerner-Ellis JP, Tirone JC, Pawelek PD, Doré C, Atkinson JL, Watkins D, et al. Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. Nat Genet. 2006;38:93–100.View ArticlePubMedGoogle Scholar
- Fenton WA, Gravel RA, Rosenblatt DS. Disorders of propionate and methylmalonate metabolism. The metabolic and molecular bases of inherited disease. 2001;2:2165–93.Google Scholar
- Lerner-Ellis JP, Anastasio N, Liu J, Coelho D, Suormala T, Stucki M, et al. Spectrum of mutations in MMACHC, allelic expression, and evidence for genotype-phenotype correlations. Hum Mutat. 2009;30:1072–81.View ArticlePubMedGoogle Scholar
- Nogueira C, Aiello C, Cerone R, Martins E, Caruso U, Moroni I, et al. Spectrum of MMACHC mutations in Italian and Portuguese patients with combined methylmalonic aciduria and homocystinuria, cblC type. Mol Genet Metab. 2008;93:475–80.View ArticlePubMedGoogle Scholar
- Chang JT, Chen YY, Liu TT, Liu MY, Chiu PC. Combined methylmalonic aciduria and homocystinuria cblC type of a Taiwanese infant with c.609G > A and C.567dupT mutations in the MMACHC gene. Pediatr Neonatol. 2011;52:223–6.View ArticlePubMedGoogle Scholar
- Zhang Y, Yang YL, Hasegawa Y, Yamaguchi S, Shi CY, Song JQ, et al. Prenatal diagnosis of methylmalonic aciduria by analysis of organic acids and total homocysteine in amniotic fluid. Chin Med J (Engl). 2008;121:216–9.Google Scholar
- Inoue Y, Ohse M. Prenatal diagnosis of methylmalonic aciduria by measuring methylmalonic acid in dried amniotic fluid on filter paper using gas chromatography-mass spectrometry. Anal Bioanal Chem. 2011;400:1953–8.View ArticlePubMedGoogle Scholar
- Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39(9):1764–79.PubMedGoogle Scholar
- Komhoff M, Roofthooft MT, Westra D, Teertstra TK, Losito A, van de Kar NC, et al. Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency. Pediatrics. 2013;132(2):e540–4.View ArticlePubMedGoogle Scholar
- Liu MY, Yang YL, Chang YC, Chiang SH, Lin SP, Han LS, et al. Mutation spectrum of MMACHC in Chinese patients with combined methylmalonic aciduria and homocystinuria. J Hum Genet. 2010;55:621–6.View ArticlePubMedGoogle Scholar
- Wang F, Han LS, Hu YH, Yang YL, Ye J, Qiu WJ, et al. Analysis of gene mutations in Chinese patients with methylmalonic acidemia and homocysteinemia. Zhonghua er ke za zhi Chi J pediatr. 2009;47:189–93.Google Scholar
- Morel CF, Watkins D, Scott P, Rinaldo P, Rosenblatt DS. Prenatal diagnosis for methylmalonic acidemia and inborn errors of vitamin B12 metabolism and transport. Mol Genet Metab. 2005;86(1-2):160–71.View ArticlePubMedGoogle Scholar
- Cavicchi C, Donati MA, Funghini S, Ia Marca G, Malvagia S, Ciani F, Poggi GM, Pasquini E, Zammarchi E, Morrone A: Genetic and biochemical approach to early diagnosis in a family with mut methylmalonic aciduria. Clin Genet. 2006;69(1):72–6.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.